Deal flow picked up last week with ten IPOs pricing and raising almost $1.9 billion in proceeds. Though it was a strong week for pricings, six of the ten deals slashed...read more
Esperion Therapeutics, which is developing a treatment for elevated levels of low-density lipoprotein cholesterol, raised $70 million by offering 5.0 million shares at $14, within the range of $13 to $15. Esperion Therapeutics plans to list on the NASDAQ under...read more
For the fifth consecutive week, at least one US IPO gained 30%, as Gigamon (GIMO) climbed nearly 50%. The week's most prominent IPO, Coty (COTY), faltered though, and the third scheduled deal, Aratana Therapeutics (PETX) was delayed. Nine more IPOs,...read more
Esperion Therapeutics, a biotech focused on developing a treatment for patients with elevated levels of low-density lipoprotein cholesterol, announced terms for its IPO on Wednesday. The Plymouth, MI-based company plans to raise $63 million by offering 4.5...read more
US IPO Recap: Market picks up the pace with ten IPOs, six price below the range
Deal flow picked up last week with ten IPOs pricing and raising almost $1.9 billion in proceeds. Though it was a strong week for pricings, six of the ten deals slashed...read more
Esperion Therapeutics prices upsized IPO at $14, the midpoint of the range
Esperion Therapeutics, which is developing a treatment for elevated levels of low-density lipoprotein cholesterol, raised $70 million by offering 5.0 million shares at $14, within the range of $13 to $15. Esperion Therapeutics plans to list on the NASDAQ under...read more
US IPO Recap: Coty fades, Gigamon springs and 17 companies file or set terms
For the fifth consecutive week, at least one US IPO gained 30%, as Gigamon (GIMO) climbed nearly 50%. The week's most prominent IPO, Coty (COTY), faltered though, and the third scheduled deal, Aratana Therapeutics (PETX) was delayed. Nine more IPOs,...read more
Biotech Esperion Therapeutics sets terms for $63 million IPO
Esperion Therapeutics, a biotech focused on developing a treatment for patients with elevated levels of low-density lipoprotein cholesterol, announced terms for its IPO on Wednesday. The Plymouth, MI-based company plans to raise $63 million by offering 4.5...read more